Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report

Endothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos, German E., Caglevic, Christian, Bulnes, Juan F., Panay, Sergio E., Zapata, Mario I., Daniele, Andrés J., Rodríguez, Manuel E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724619/
https://www.ncbi.nlm.nih.gov/pubmed/36483627
http://dx.doi.org/10.3389/fcvm.2022.1060813
Descripción
Sumario:Endothelial Growth Factor Receptor (EGFR) mutations are frequently found among NSCLC patients. Second-generation Tyrosine Kinase Inhibitor (TKI) Afatinib is frequently used in this population of patients achieving better results than cytotoxic chemotherapy in terms of survival and progression. Afatinib-related cardiotoxicity has been rarely reported. Here we comment on a clinical case of a Takotsubo Cardiomyopathy Afatinib-induced in an NSCLC patient.

Ejemplares similares